<DOC>
	<DOCNO>NCT01264315</DOCNO>
	<brief_summary>Rationale : We recently report study overall event free survival newly diagnose myeloma patient receive autologous transplant follow allograft HLA-identical sibling superior compare undergoing double autologous transplant . A large multicenter study Gruppo Italiano Trapianti di Midollo ( GITMO ) , co-ordinated group recently close , employ tandem auto-allo approach newly diagnose patient confirm achievement prolonged event free overall survival . Importantly , achievement least good partial remission time allografting confer significant advantage event-free-survival ( HR 0,23 , CI 0,11-0,48 ; p=0,0001 ) overall survival ( HR 0,26 ; CI 0,09-0,79 ; p=0,02 ) . Moreover , recent advance understand pathogenesis multiple myeloma identify specific signal pathways become target biologically-based drug thalidomide , bortezomib lenalidomide employ several trial , include allograft . The aim current proposal combine post-transplant efficacy graft-vs.-myeloma anti-myeloma effect lenalidomide newly diagnose myeloma patient HLA-identical sibling treated tandem autograft-allograft approach . Maintenance/consolidation response may key factor improve rate clinical molecular ( prelude cure ) remission prolong overall event free survival allografting . We would like investigate safety efficacy lenalidomide consolidation/maintenance therapy patient undergo tandem autologous-allogeneic transplant . Objectives study : To evaluate 1 ) toxicity tolerability lenalidomide allografting ; 2 ) To evaluate efficacy lenalidomide induce complete remission , define negative immunofixation , 12 month allografting ; 3 ) overall-survival ; 4 ) event-free survival ; 5 ) molecular remission rate . Furthermore plan compare molecular remission rate patient treat lenalidomide tandem auto-allo transplant double autologous transplant monitor minimal residual disease patient achieve clinical CR lenalidomide . Patient Selection : Patients newly diagnose multiple myeloma HLA identical sibling suitable PBSC donation include . Complete cytogenetic analysis diagnosis require . The patient must capacity give informed consent . Age &gt; 18 &lt; 65 . Negative pregnancy test willing use contraceptive technique 12 month follow treatment require . Only unfitted patient exclude . Treatment plan : Lenalidomide start 6 month post-allotransplant dose 10 mg/day continuously patient ( unless molecular CR ) , follow condition present : - absolute neutrophil count &gt; 1 x 109/L without use growth factor ; - platelet count &gt; 75 x 109/L without transfusion support ; - calculate measured creatinine clearance : ≥ 20 mL/minute ; - total bilirubin &lt; 2 x upper limit normal , - AST ALT &lt; 2.5 x upper limit normal - le 1 mg/kg/day prednisone , 2 immunosuppressive drug steroid control GVHD ( immunosuppression require control GVHD , maintenance therapy lenalidomide hold criterion satisfy ) Treatment continue without interruption , unless tolerate , unacceptable adverse event experience progressive disease occur . Moreover , lenalidomide discontinue patient achieve maintain molecular remission 2 consecutive control least 6 week apart . Safety section - dose modification plan : During study patient monitor occurrence side effect . Toxicity event grade accord NCI toxicity criterion . In case severe toxicity , lenalidomide dose reduced withheld outline protocol . Statistical section : - Total patient sample size : 53 . This phase 2 study design accord Simon 's two-stage Minimax Design . An early stopping rule establish interrupt study case futility ( non satisfactory response rate ) . In stage I 27 patient enrol ; &lt; 14 complete remission observe , trial stop . In stage II 26 patient enrol . If ≥ 32 response observe , conclude lenalidomide maintenance active increase complete remission rate auto-allograft . Analysis plan : Toxicity monitoring incorporate study design require trial terminate initial stage number observe toxicity ( treatment relate death ) excessive .</brief_summary>
	<brief_title>Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant</brief_title>
	<detailed_description>A. Pre-transplant phase : Induction Therapy Patients start induction treatment lenalidomide dexamethasone ( RD ) 4 cycle every 28 day ( detail also GIMEMA protocol RV-MM-PI-209 ) : - Lenalidomide give orally dose 25 mg/day 21 day follow 7 day rest period ( day 22 28 ) , - Dexamethasone give orally dose 40 mg day 1 , 8 , 15 22 every 28 day . If patient relapse RD end 4th cycle , induction treatment may hold stem cell collection may attempt cyclophosphamide accord physician willing . For dose reduction induction therapy see Appendix O. Antithrombotic prophylaxis per protocol RV-MM-PI-209 . For patient previously enrol protocol RV-MM-PI-209 , recommend prophylaxes aspirin patient without additional thrombotic risk factor , low molecular weight heparin ( LMWH ) 100 U/kg others . Otherwise , induction schema accept provided thalidomide , lenalidomide bortezomib , alone combination , include . B . Peripheral Blood Stem Cell ( PBSC ) Mobilization collection After 1-2 month completion last induction course , patient undergo PBSC mobilization cyclophosphamide 4 g/m2 G-CSF ( 10 ug/kg/day start day 5 completion PBSC collection ) collect adequate number PBSC ( 4 10 x 106/kg CD 34+ cell ) . Patients fail collect minimum 4 x 106/kg CD 34+ cell receive second course cyclophosphamide second mobilization attempt . Patients fails collect minimum 4 x 106/kg CD 34+ withdrawn study . C. High-Dose Melphalan / Autologous PBSC Transplant High dose melphalan give 4 8 week high dose cyclophosphamide . 1 . Melphalan administer cumulative dose 200 mg/m2 . This give one dose infuse day -2 . Dose calculate accord participate institutional standard practice use body weight . High dose Melphalan administer via central catheter per single center procedure . 2 . Peripheral Blood Stem Cell Bone Marrow Infusion : Infuse &gt; 2 x 106 CD 34+ cell /kg , hydration requirement , pre-medication per guideline institution . 3 . G-CSF : Administer G-CSF 5 ug/kg/day subcutaneously intravenously day +3 ANC &gt; 1000 3 day . D. Allogeneic transplant phase : Non-myeloablative PBSC Allografting Pre-conditioning Upon recovery high-dose melphalan , 40-120 day post autografting ( preferably within 60 day ) patient proceed nonmyeloablative allograft . If indicate , radiation high risk skeletal lesion may give pre-transplant . If interval exceeds 120 day , present PCC discussion approval . Recovery high-dose melphalan define patient achieve follow clinical criterion receive high dose melphalan : 1. mucositis gastrointestinal symptom resolve , hyperalimentation intravenous hydration ; 2. complete steroid autologous GVHD ; 3 . LFT / renal function value within inclusion criterion initial autograft ; 4. IV antibiotic amphotericin document infection ; 5. patient CMV antigenemia negative ; 6. patient experienced CMV infection post-autograft , must complete therapy Ganciclovir Foscarnet therapy &gt; two week remain CMV antigenemia negative ; 7. complete administration radiotherapy ; 8. patient fulfill criterion , discuss principle investigator recommendation time allograft .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Newly diagnose multiple myeloma patient HLA identical sibling suitable PBSC donation treat induction thalidomide bortezomib lenalidomide conteining regime . 2 . Complete cytogenetic analysis diagnosis , include FISH analysis chromosome deletion 13 17 , translocation ( 4 ; 14 ) ( 11 ; 14 ) ( 14 ; 16 ) . 3 . The patient must capacity give informed consent . 4 . Age &gt; 18 &lt; 65 5 . If female , patient either postmenopausal since least 24 consecutive month surgically sterilize agree practice sexual abstinence use two reliable method contraception ( e.g . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide ) duration study 6 . If male , patient agree practice sexual abstinence use latex condom sexual contact woman childbearing potential duration study 7 . Negative pregnancy test 1 . Karnofsky score less 60 ( see appendix C ) , unless due solely myeloma 2 . Left ventricular ejection fraction le 40 % , symptomatic coronary artery disease cardiac failure require therapy 3 . Bilirubin great 2 X upper limit normal , SGPT SGOT &gt; 4 X upper limit normal 4 . DLCO &lt; 40 % ( correct ) receive continuous supplemental oxygen . 5 . Creatinine clearance &lt; 40 cc/min time initial autografting evaluation . 6 . Patients poorly control hypertension 7 . Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) . 8 . Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence 9 . Seropositive HIV 10 . Fertile men woman unwilling use contraceptive technique 12 month follow treatment . 11 . To evaluate toxicity tolerability lenalidomide allografting 12 . To evaluate efficacy lenalidomide induce complete remission 12 month allografting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Tandem Autologous-Allogeneic Transplant</keyword>
</DOC>